The Measuring Parkinson's Disease Progression study aims to use MRI scans and a controlled
dose of levodopa to find a biomarker (objective measurement) of Parkinson's disease (PD).
Biomarkers would help determine the effectiveness of therapies in slowing or stopping PD
progression, and accelerate the pace of research.
Phase:
Phase 1
Details
Lead Sponsor:
Kevin J. Black, MD
Collaborator:
The Michael J. Fox Foundation for Parkinson's Research